Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats

European Journal of Pharmacology

Volumn 643, Issue 2-3, 2010, Pages 180-187

  Alboni, Silvia ^a   Benatti, Cristina ^a   Capone, Giacomo ^a,b   Corsini, Daniela ^a   Caggia, Federica ^a   Tascedda, Fabio ^a   Mendlewicz, Julien ^b   Brunello, Nicoletta ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ERASME HOSPITAL   (Belgium)

Author keywords

BDNF; CREB; Escitalopram; Hippocampus; Neuroplasticity; Prefrontal cortex

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM RESPONSIVE FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESCITALOPRAM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; MALE; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TIME;

EID: 77955268951     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.028     Document Type: Article

References (66)

1. Arnsten A.F., Goldman-Rakic P.S. Selective prefrontal cortical projections to the region of the locus coeruleus and raphe nuclei in the rhesus monkey. Brain Res. 1984, 306(9-1):18.
2. Barbiero V.S., Giambelli R., Musazzi L., Tiraboschi E., Tardito D., Perez J., Drago F., Racagni G., Popoli M. Chronic antidepressants induce redistribution and differential activation of alphaCaM kinase II between presynaptic compartments. Neuropsychopharmacology 2007, 32:2511-2519.
3. Bergami M., Santi S., Formaggio E., Cagnoli C., Verderio C., Blum R., Berninger B., Matteoli M., Canossa M. Uptake and recycling of pro-BDNF for transmitter-induced secretion by cortical astrocytes. J. Cell Biol. 2008, 183:213-221.
4. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol. Psychiatry 2006, 59:1144-1150.
5. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur. Neuropsychopharmacol. 2003, 13:57-66.
6. Blom J.M., Tascedda F., Carra S., Ferraguti C., Barden N., Brunello N. Altered regulation of CREB by chronic antidepressant administration in the brain of transgenic mice with impaired glucocorticoid receptor function. Neuropsychopharmacology 2002, 26:605-614.
7. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 2006, 21:219-225.
8. Capone G., Alboni S., Benatti C. Rapid effect of escitalopram in a behavioural model of depression: the chronic escape deficit. Eur. Neuropsychopharmacol. 2006, 16(S4):S290.
9. Carvalho A.L., Caldeira M.V., Santos S.D., Duarte C.B. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br. J. Pharmacol. 2008, 153:S310-S324.
10. Carvalho A.F., Machado J.R., Cavalcante J.L. Augmentation strategies for treatment-resistant depression. Curr. Opin. Psychiatry 2009, 22:7-12.
11. Castrén E. Neurotrophic effects of antidepressant drugs. Curr. Opin. Pharmacol. 2004, 4:58-64.
12. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 2001, 21:9917-9929.
13. Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci. 1997, 17:2295-2313.
14. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog. Brain Res. 2000, 126:413-431.
15. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
16. Duman C.H., Schlesinger L., Kodama M., Russell D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 2007, 61:661-670.
17. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 2003, 23:7311-7316.
18. Figurov A., Pozzo-Miller L.D., Olafsson P., Wang T., Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996, 381:706-709.
19. Gaykema R.P., van Weeghel R., Hersh L.B., Luiten P.G. Prefrontal cortical projections to the cholinergic neurons in the basal forebrain. J. Comp. Neurol. 1991, 303:563-583.
20. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., Taylor J.R. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol. Psychiatry 2008, 63:353-359.
21. Hollerman J.R., Tremblay L., Schultz W. Involvement of basal ganglia and orbitofrontal cortex in goal-directed behavior. Prog. Brain Res. 2000, 126:193-215.
22. Holmes A., Wellman C.L. Stress-induced prefrontal reorganization and executive dysfunction in rodents. Neurosci. Biobehav. Rev. 2009, 33:773-783.
23. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
24. Jacobsen J.P., Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res. 2004, 1024:183-192.
25. Jodo E., Chiang C., Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998, 83:63-79.
26. Kennedy S.H., Javanmard M., Vaccarino F.J. A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Can. J. Psychiatry 1997, 42:467-475.
27. Koenigs M., Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav. Brain Res. 2009, 201:239-243.
28. Korte M., Carroll P., Wolf E., Brem G., Thoenen H., Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl Acad. Sci. USA 1995, 92:8856-8860.
29. Kozisek M.E., Middlemas D., Bylund D.B. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol. Ther. 2008, 117:30-51.
30. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
31. Kuipers S.D., Trentani A., Westenbroek C., Bramham C.R., Korf J., Kema I.P., Ter Horst G.J., Den Boer J.A. Unique patterns of FOS, phospho-CREB and BrdU immunoreactivity in the female rat brain following chronic stress and citalopram treatment. Neuropharmacology 2006, 50:428-440.
32. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
33. Lessmann V., Brigadski T. Mechanisms, locations, and kinetics of synaptic BDNF secretion: an update. Neurosci. Res. 2009, 65:11-22.
34. Lu B., Pang P.T., Woo N.H. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 2005, 6:603-614.
35. Maisonpierre P.C., Le Beau M.M., Espinosa R., Ip N.Y., Belluscio L., de la Monte S.M., Squinto S., Furth M.E., Yancopoulos G.D. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991, 10:558-568.
36. Manji H.K., Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull. 2001, 35:5-49.
37. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008, 33:73-83.
38. Matsumoto T., Rauskolb S., Polack M., Klose J., Kolbeck R., Korte M., Barde Y.A. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci. 2008, 11:131-133.
39. Mayberg H.S. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin. N. Am. 2003, 13:805-815.
40. Miller A.H., Raison C.L. Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology 2006, 31:2089-2090.
41. Miró X., Pérez-Torres S., Artigas F., Puigdomènech P., Palacios J.M., Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002, 43:1148-1157.
42. Montgomery S.A., Loft H., Sanchez C., Reines E.H., Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol. Toxicol. 2001, 88:282-286.
43. Nagappan G., Zaitsev E., Senatorov V.V., Yang J., Hempstead B.L., Lu B. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc. Natl Acad. Sci. USA 2009, 106:1267-1272.
44. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen H., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 2002, 52:503-528.
45. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997, 283:1305-1322.
46. Owens M.J., Knight D.L., Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 2001, 50:345-350.
47. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306:487-491.
48. Patterson S.L., Abel T., Deuel T.A., Martin K.C., Rose J.C., Kandel E.R. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 1996, 16:1137-1145.
49. Qi X., Lin W., Li J., Li H., Wang W., Wang D., Sun M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol. Dis. 2008, 31:278-285.
50. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, USA. (4th edn).
51. Reed A.L., Anderson J.C., Bylund D.B., Petty F., El Refaey H., Happe H.K. Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats. Psychopharmacology (Berl) 2009, 205:249-259.
52. Rex C.S., Lin C.Y., Kramár E.A., Chen L.Y., Gall C.M., Lynch G. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J. Neurosci. 2007, 27:3017-3029.
53. Robbins T.W. Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J. Comp. Neurol. 2005, 493:140-146.
54. Rösch H., Schweigreiter R., Bonhoeffer T., Barde Y.A., Korte M. The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus. Proc. Natl Acad. Sci. USA 2005, 102:7362-7367.
55. Sanchez C., Gruca P., Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav. Pharmacol. 2003, 14:465-470.
56. Satoh Y., Endo S., Ikeda T., Yamada K., Ito M., Kuroki M., Hiramoto T., Imamura O., Kobayashi Y., Watanabe Y., Itohara S., Takishima K. Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. J. Neurosci. 2007, 27:10765-10776.
57. Schulte-Herbrüggen O., Fuchs E., Abumaria N., Ziegler A., Danker-Hopfe H., Hiemke C., Hellweg R. Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J. Neurosci. Res. 2009, 87:2551-2560.
58. Tao X., West A.E., Chen W.G., Corfas G., Greenberg M.E. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron 2002, 33:383-395.
59. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 2006, 58:115-134.
60. Taylor M., Norbury R., Murphy S., Rudebeck S., Jezzard P., Cowen P. Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. J. Psychopharmacol. 2009, 10.1177/0269881109105679.
61. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
62. Vertes R.P. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat. Neuroscience 2006, 29:1-20.
63. West A.E., Griffith E.C., Greenberg M.E. Regulation of transcription factors by neuronal activity. Nat. Rev. Neurosci. 2002, 3:921-931.
64. Woo N.H., Teng H.K., Siao C.J., Chiaruttini C., Pang P.T., Milner T.A., Hempstead B.L., Lu B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat. Neurosci. 2005, 8:1069-1077.
65. Yang F., Je H.S., Ji Y., Nagappan G., Hempstead B., Lu B. Pro-BDNF-induced synaptic depression and retraction at developing neuromuscular synapses. J. Cell Biol. 2009, 185:727-741.
66. Zarubin T., Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15:11-18.